Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Palaia

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Critical Reviews in Oncology/Hematology|April 14, 2018
Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trialsC Marchetti, F De Felice, A Di Pinto, et al.
Frontiers in Oncology|December 5, 2022
Post treatment imaging in patients with local advanced cervical carcinomaS Ciulla, V Celli, A A Aiello, et al.
Critical Reviews in Oncology/Hematology|November 19, 2018
Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysisC Marchetti, F De Felice, S Boccia, et al.
Minerva Ginecologica|February 11, 2009
[Prevention of postoperative adhesions]I Palaia, T Boni, R Angioli, et al.
Cancer Treatment Reviews|November 13, 2015
Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patientsC Marchetti, I Palaia, F De Felice, et al.
Current Molecular Medicine|September 1, 2012
Past, present and future strategies of immunotherapy in gynecological malignanciesF Bellati, C Napoletano, I Ruscito, et al.
Annals of Surgical Oncology|March 25, 2015
Secondary Cytoreduction in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Institution ExperienceA Musella, C Marchetti, I Palaia, et al.
Cellular and Molecular Biology (Noisy-Le-Grand, France)|November 1, 2015
PARP inhibition: A promising therapeutic target in ovarian cancerA Musella, C Marchetti, M L Gasparri, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Critical Reviews in Oncology/Hematology|April 14, 2018
Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trialsC Marchetti, F De Felice, A Di Pinto, et al.
Frontiers in Oncology|December 5, 2022
Post treatment imaging in patients with local advanced cervical carcinomaS Ciulla, V Celli, A A Aiello, et al.
Critical Reviews in Oncology/Hematology|November 19, 2018
Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysisC Marchetti, F De Felice, S Boccia, et al.
Minerva Ginecologica|February 11, 2009
[Prevention of postoperative adhesions]I Palaia, T Boni, R Angioli, et al.
Cancer Treatment Reviews|November 13, 2015
Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patientsC Marchetti, I Palaia, F De Felice, et al.
Current Molecular Medicine|September 1, 2012
Past, present and future strategies of immunotherapy in gynecological malignanciesF Bellati, C Napoletano, I Ruscito, et al.
Annals of Surgical Oncology|March 25, 2015
Secondary Cytoreduction in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Institution ExperienceA Musella, C Marchetti, I Palaia, et al.
Cellular and Molecular Biology (Noisy-Le-Grand, France)|November 1, 2015
PARP inhibition: A promising therapeutic target in ovarian cancerA Musella, C Marchetti, M L Gasparri, et al.
Pageof 2